CD274 and metastatic neoplasm: Although treatment for recalcitrant NRAS-mutant metastatic tumors has recently advanced for PDL1-expressing patients, with immunotherapies anti–PD-1, anti-PD-L1, and anti-CTLA4 proving efficacious in first-line treatments, a majority of patients remain unresponsive, as chemotherapy with dacarbazine (DTIC), temozolomide, or carboplatin added as supplementary treatments show limited success [10].